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Abstract
There has been increasing interest in the role of malaria drugs in preventing malaria transmission from humans to
mosquitoes, which would help augment malaria control and elimination strategies. Nevertheless, only one stage in
the malaria parasite life cycle, the gametocyte, is infectious to mosquitoes. The Worldwide Antimalarial Resistance
Network (WWARN) have analyzed data from 48,840 patients from 141 clinical trials in order to define the nature
and determinants of gametocyte clearance following artemisinin combination treatment (ACT) for symptomatic
malaria infections. However, the presence of gametocytes does not always predict their infectivity, meaning that
the microscopy-based methods used by the WWARN investigators represent an imperfect surrogate marker of
transmissibility. Their findings, that some ACTs clear gametocytes faster than others, should be interpreted in
light of these limitations and important gaps in our understanding of the biology and epidemiology of malaria
transmission.
Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0621-7
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Background
Global improvements in malaria control over the last
15 years have been greater than at any other time in his-
tory, with annual deaths from malaria having almost
halved since 2000 [1]. The scale of this success rein-
forces the notion that the complete global eradication of
malaria may be an attainable goal. With this in mind, the
pharmacological properties of antimalarial drugs have re-
cently been regarded from a different perspective [2] – in
addition to curing symptomatic infections, the broader
public health implications with regards to their role in re-
ducing ongoing malaria transmission at the population
level must also be considered.
The success of malaria elimination strategies will
fundamentally rest on interrupting the cycle of parasite
transmission between the Anopheles mosquito vector and
humans. Strategies can target not only transmission from
mosquito to human but also from human to mosquito,
prompting renewed interest both in so-called “trans-
mission-blocking” human malaria vaccines and the role
of antimalarial drugs for preventing transmission to
mosquitoes.
Gametocytes arise mainly as progeny of “asexual”
blood-stage parasites (merozoites). The maturation of
Plasmodium falciparum gametocytes within humans has
been divided into five morphologically and transcription-
ally distinct stages (Fig. 1) [3]. Only the most mature
stage 5 gametocytes are infectious to mosquitoes and,
following ingestion, travel to the mosquito mid-gut to
develop into gametes. If both male and female gametes
are present, sexual reproduction ensues, leading ultimately
to sporozoites able to infect humans. Therefore, gameto-
cytes are imperative to human-to-mosquito transmission
for all malaria species. P. falciparum gametocytes have a
highly distinctive morphology, meaning that they can eas-
ily be detected, distinguished from other life-stages, and
quantified using conventional microscopic techniques.
The finding of gametocytes on a standard Giemsa-stained
blood film (together with metrics derived from their
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concentration over time) has therefore been used as an
easily generated indicator of an individual’s potential for
onward transmission of malaria [4, 5].
Some antimalarial drugs clear gametocytes from
the blood more rapidly than others
Antimalarial drugs differ in their relative activity on the
various life-cycle stages of the malaria parasite, a prop-
erty often termed “stage specificity”, which can manifest
through the more effective gametocytocidal activity of
certain drugs over others [6]. Although new in vitro
techniques can assess drug gametocytocidal activity [6],
in vivo data is needed to establish drug activity within
the human host.
Artemisinin combination therapies (ACTs) are now
the mainstay in the treatment of most malaria cases
worldwide [7]. Five ACTs, each utilizing a different
“partner drug” are currently approved for use. It could
be argued that differences in gametocytocidal activity be-
tween these ACTs could have important public health
implications.
In a research article published in BMC Medicine [8],
the WWARN investigators identify clear differences
between different ACTs with regards to gametocyte
clearance. They show that those with 4-aminoquinoline
partner drugs (dihydroartemisinin-piperaquine and
artesunate-amodiaquine) clear gametocytes significantly
slower than those with aryl-amino alcohol and related struc-
tures (artesunate-mefloquine and artemether-lumefantrine).
These data infer that, whilst 4-aminoquinoline-based ACTs
may be perfectly effective in curing an individual pa-
tient’s clinical malaria infection, they could be inferior
from a public health perspective given their reduced ef-
fectiveness at preventing onward transmission. It could
be argued that artesunate-mefloquine and artemether-
lumefantrine have advantages for malaria control, espe-
cially if elimination is the ultimate aim. Others have also
argued that primaquine, a drug with potent gametocytoci-
dal activity, should be routinely deployed as adjunctive
therapy to further reduce transmission following ACT
treatment [9].
How much does gametocyte clearance actually
really matter?
There are important reasons why the differences in
gametocyte clearance identified by the WWARN inves-
tigators should be interpreted with caution. Firstly,
microscopic evidence of gametocytaemia may not neces-
sarily be as accurate an indicator of human-to-mosquito
transmissibility as might be expected. Indeed, microscopy
cannot distinguish viable, living parasites from those that
are dead or have been affected by a drug in a way that
compromises their infectivity [10, 11]. Further, routine mi-
croscopy usually does not distinguish between the most
mature infective forms and the less mature non-infective
forms. Therefore, considering that drugs may have dif-
fering gametocytocidal activity at the various stages of
development, simply measuring the total numbers of
Fig. 1 The life cycle of Plasmodium falciparum, demonstrating how onward transmission occurs from one human host to the next. Drugs with
“transmission-blocking” properties can act on any of the sexual stages of the parasite (gametocytes from stage I to V) occurring within the human
host (pink-shaded area). However, because a mosquito’s blood meal will contain concentrations of any drug present at the time of biting, drugs
administered to humans can also have transmission-blocking potential through their activity on stages present in the mosquito mid-gut
(yellow-shaded area)
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gametocytes can be misleading [4]. Finally, microscopy
is relatively insensitive and methods based on reverse-
transcriptase quantitative PCR can unmask both a
much larger potentially infective population and longer
durations of potential infectivity following treatment
[4]. In combination, these and other factors indicate
that there is no simple linear relationship between
gametocyte density and true infectivity. Indeed, some
individuals with little or no gametocytemia are infec-
tious and others with very high gametocytemia are
non-infectious. Therefore, microscopy-based metrics of
blood gametocyte clearance kinetics can only be consid-
ered “indirect” or “surrogate” markers of true infectivity to
mosquitoes.
Ideal “gold standard” tests should rely on experiments
known as direct (membrane) feeding assays. These require
mosquitoes to be allowed to feed on human subjects (or at
least on fresh human blood through an artificial mem-
brane), after which mosquito mid-guts are dissected to
determine whether oocysts have been formed. Yet, be-
ing labor-intensive and requiring significant insectary
and laboratory facilities in a malaria endemic setting, it
is not surprising that data from definitive studies of this
type are lacking. Nevertheless, when such studies have
been performed, they have generated some surprising
and counterintuitive findings. For example, a previously
widely-held belief was that, based on in vitro and in vivo
observations of very high and prolonged gametocyte
prevalence following treatment with the antimalarial
sulfadoxine-pyrimethamine, this drug was a particularly
bad culprit for facilitating onward transmission. However,
direct feeding experiments showed these gametocytes are,
in fact, poorly infective [10, 11]. Another recent study
evaluating adjunctive gametocytocidal treatment (prima-
quine added to artemether-lumefantrine) showed that only
one of 49 subjects in the control group (who received only
artemether-lumefantrine without primaquine) was able to
infect mosquitoes following treatment despite over 30 %
having microscopically detectable post-treatment gameto-
cytemia [12]. This data challenges recent calls for routine
deployment of adjunctive primaquine gametocytocidal
treatment following ACT case management [9] and
demonstrates how important direct infectivity data are
for assessing the effect of different treatments on malaria
transmission.
Uncertainties in transmissibility within
sub-populations
Furthermore, there is a singular, crucial, unresolved epi-
demiological question that must be urgently addressed.
In endemic settings, at any one time, the total transmis-
sible biomass can be thought of as residing in three sep-
arate sub-populations: (1) those who have become
unwell with malaria, but have yet to be treated; (2) those
who have been treated and may remain infectious for a
variable period (depending on drug and other factors);
and (3) the population of chronic asymptomatic carriers
(who are unlikely to receive antimalarial treatment at
all). The relative contribution of each group to overall
transmission will depend on three factors that may vary
according to the epidemiological setting: (1) the size of
each group relative to one another; (2) the duration for
which individuals in each group remain infectious; and
(3) how infectious individuals in each group are relative
to those in the other groups. In other words, what is the
probability that a single mosquito feed will result in
human-mosquito transmission and how does this vary
between groups? In the absence of good data from direct
feeding experiments, this last factor remains essentially
unclear. For instance, because asymptomatic carriers
have generally lower concentrations of circulating game-
tocytes (often at sub-microscopic levels) it is uncertain
just how infectious they are. However, because they usu-
ally represent the largest of the three groups and since
they may have (potentially) much longer durations of in-
fectivity (months or even years, compared with days or
weeks in the other two groups) asymptomatic carriers
could possibly represent a substantial contributor to
human-mosquito transmission in many epidemiological
settings. One mathematical modeling study suggests this
could be to such a degree that post-treatment gametocy-
taemia (in the second group) becomes irrelevant [13].
However, such modeling exercises rely on assumptions
regarding the infectivity of asymptomatic carriers that
are open to debate. These uncertainties can only be re-
solved with robust infectivity data from direct feeding
studies that include asymptomatic carriers living in
endemic areas.
Conclusions
The WWARN investigators have again demonstrated
the impressive power of pooling data from a large number
of studies and how this can unearth significant between-
treatment differences in pharmacodynamic endpoints that
would not ordinarily be detected. However, we must
accept that its findings are subject to limitations inherent
both in their use of an imperfect, indirect, surrogate bio-
marker for transmission and our currently limited under-
standing of the relative contribution of symptomatic and
asymptomatic infections under different transmission sce-
narios. We must therefore be careful to distinguish the
statistical significance of its findings from their actual clin-
ical or public health implications. To this effect, we must
first address fundamental gaps in our knowledge of the
biology and epidemiology of malaria transmission through
field studies using direct feeding assays, including in
asymptomatic carriers. These studies are difficult and
resource intensive to perform, but not impossible. The
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significant investment required is more than justified
by the returns they are likely to generate for guiding
policy and future research in malaria.
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